{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:00:45Z","timestamp":1782230445402,"version":"3.54.5"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004054","name":"King Abdulaziz University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.vaccine.2025.127975","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T03:25:36Z","timestamp":1763263536000},"page":"127975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Intranasal CD40-targeted recombinant MERS-CoV S1 protein is superior to intramuscular immunization in eliciting systemic and mucosal immune responses in mice"],"prefix":"10.1016","volume":"69","author":[{"given":"Muhammad Yasir","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najwa D.","family":"Aljehani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rwaa H.","family":"Abdulal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishah","family":"Ghazwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem M.","family":"Alsulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mais","family":"Eyouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salima","family":"Shebbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Basabrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.","family":"Sanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asem A.","family":"Alsharef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesam H.","family":"Abdulaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwag","family":"Albukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishtiaq","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid A.","family":"Alluhaybi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarfa","family":"Altorki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowa","family":"Alhabbab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maimonah","family":"Alghanmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayat","family":"Zawawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turki S.","family":"Abujamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Algaissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathya N.","family":"Thulasi Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Alfaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrah S.","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala A.","family":"Azhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Bakur","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar M.","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.vaccine.2025.127975_bb0005","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127975_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232790","article-title":"Cross-sectional prevalence study of MERS-CoV in local and imported dromedary camels in Saudi Arabia, 2016-2018","volume":"15","author":"Tolah","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2025.127975_bb0015","author":"World Health Organization"},{"issue":"7461","key":"10.1016\/j.vaccine.2025.127975_bb0020","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature12328","article-title":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26","volume":"500","author":"Lu","year":"2013","journal-title":"Nature"},{"issue":"7440","key":"10.1016\/j.vaccine.2025.127975_bb0025","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127975_bb0030","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbrc.2004.09.106","article-title":"Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine","volume":"324","author":"He","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"26","key":"10.1016\/j.vaccine.2025.127975_bb0035","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1016\/j.vaccine.2006.04.054","article-title":"Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine","volume":"24","author":"He","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127975_bb0040","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV--a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127975_bb0045","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127975_bb0050","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","article-title":"Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial","volume":"20","author":"Koch","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127975_bb0055","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","article-title":"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial","volume":"20","author":"Folegatti","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127975_bb0060","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S2666-5247(21)00193-2","article-title":"Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial","volume":"3","author":"Bosaeed","year":"2022","journal-title":"Lancet Microbe"},{"issue":"301","key":"10.1016\/j.vaccine.2025.127975_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac7462","article-title":"A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates","volume":"7","author":"Muthumani","year":"2015","journal-title":"Sci Transl Med"},{"issue":"6268","key":"10.1016\/j.vaccine.2025.127975_bb0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.aad1283","article-title":"An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels","volume":"351","author":"Haagmans","year":"2016","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127975_bb0075","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3390\/vaccines10081330","article-title":"Immunogenicity of high-dose MVA-based MERS vaccine candidate in mice and camels","volume":"10","author":"Alharbi","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127975_bb0080","doi-asserted-by":"crossref","first-page":"16292","DOI":"10.1038\/s41598-019-52730-4","article-title":"Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels","volume":"9","author":"Alharbi","year":"2019","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127975_bb0085","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S2095-3119(17)61660-5","article-title":"Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels","volume":"16","author":"Liu","year":"2017","journal-title":"J Integr Agric"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127975_bb0090","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/v11030212","article-title":"Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas","volume":"11","author":"Adney","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2025.127975_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.823949","article-title":"Inactivated rabies virus vectored MERS-coronavirus vaccine induces protective immunity in mice, camels, and alpacas","volume":"13","author":"Chi","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127975_bb0100","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/infdis\/jiz137","article-title":"A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model","volume":"220","author":"Hashem","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127975_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2023.199156","article-title":"MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection","volume":"334","author":"Tai","year":"2023","journal-title":"Virus Res"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127975_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220196","article-title":"Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length spike protein of Middle East respiratory syndrome coronavirus","volume":"14","author":"Kim","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2025.127975_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/srep44875","article-title":"Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein","volume":"7","author":"Al-Amri","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127975_bb0120","doi-asserted-by":"crossref","first-page":"7712","DOI":"10.1038\/ncomms8712","article-title":"Evaluation of candidate vaccine approaches for MERS-CoV","volume":"6","author":"Wang","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127975_bb0125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/v12010125","article-title":"Characterization of the immune response of MERS-CoV vaccine candidates derived from two different vectors in mice","volume":"12","author":"Li","year":"2020","journal-title":"Viruses"},{"issue":"24","key":"10.1016\/j.vaccine.2025.127975_bb0130","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01176-20","article-title":"Cross-protection against MERS-CoV by prime-boost vaccination using viral spike DNA and protein","volume":"94","author":"Choi","year":"2020","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127975_bb0135","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1080\/22221751.2020.1760735","article-title":"Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV","volume":"9","author":"Okba","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127975_bb0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s42522-022-00068-9","article-title":"Protective efficacy of an RBD-based Middle East respiratory syndrome coronavirus (MERS-CoV) particle vaccine in llamas","volume":"4","author":"Rodon","year":"2022","journal-title":"One Health Outlook"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127975_bb0145","doi-asserted-by":"crossref","first-page":"722","DOI":"10.4049\/jimmunol.1300093","article-title":"CD40 ligand preferentially modulates immune response and enhances protection against influenza virus","volume":"193","author":"Hashem","year":"2014","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127975_bb0150","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/mi.2014.59","article-title":"Targeting the HA2 subunit of influenza a virus hemagglutinin via CD40L provides universal protection against diverse subtypes","volume":"8","author":"Fan","year":"2015","journal-title":"Mucosal Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127975_bb0155","doi-asserted-by":"crossref","first-page":"16648","DOI":"10.1038\/s41598-018-34999-z","article-title":"Targeting CD40 enhances antibody- and CD8-mediated protection against respiratory syncytial virus infection","volume":"8","author":"Muralidharan","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127975_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.785349","article-title":"DNA based vaccine expressing SARS-CoV-2 spike-CD40L fusion protein confers protection against challenge in a Syrian Hamster model","volume":"12","author":"Tamming","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127975_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101325","article-title":"Lipid nanoparticle encapsulation of a Delta spike-CD40L DNA vaccine improves effectiveness against omicron challenge in Syrian hamsters","volume":"32","author":"Tamming","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127975_bb0170","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2427792","article-title":"Dissecting immunological mechanisms underlying influenza viral nucleoprotein-induced mucosal immunity against diverse viral strains","volume":"13","author":"Zhang","year":"2024","journal-title":"Emerg Microbes Infect"},{"issue":"6557","key":"10.1016\/j.vaccine.2025.127975_bb0175","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/378617a0","article-title":"Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand","volume":"378","author":"Grewal","year":"1995","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127975_bb0180","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.4049\/jimmunol.149.12.3817","article-title":"Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help","volume":"149","author":"Lederman","year":"1992","journal-title":"J Immunol"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2025.127975_bb0185","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1359-6101(03)00024-8","article-title":"The CD40-CD154 interaction in B cell-T cell liaisons","volume":"14","author":"Bishop","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127975_bb0190","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3390\/vaccines11111704","article-title":"Advancements in vaccine adjuvants: the journey from alum to nano formulations","volume":"11","author":"Moni","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127975_bb0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.0105-2896.2004.00148.x","article-title":"Use of CpG oligodeoxynucleotides as immune adjuvants","volume":"199","author":"Klinman","year":"2004","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127975_bb0200","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41541-022-00571-0","article-title":"A potent, broadly protective vaccine against SARS-CoV-2 variants of concern","volume":"7","author":"Wang","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"26","key":"10.1016\/j.vaccine.2025.127975_bb0205","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1016\/j.vaccine.2022.05.007","article-title":"Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern","volume":"40","author":"Pollet","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127975_bb0210","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/5279979","article-title":"A modified recombinant DNA-based SARS-CoV-2 vaccine expressing stabilized Uncleavable spike protein elicits humoral and cellular immunity against various SARS-CoV-2 variants of concern","volume":"2023","author":"Abdulal","year":"2023","journal-title":"Transbound Emerg Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127975_bb0215","first-page":"53","article-title":"ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks","volume":"7","author":"Alfaleh","year":"2023","journal-title":"Antib Ther"},{"key":"10.1016\/j.vaccine.2025.127975_bb0220","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fmicb.2020.02020","article-title":"Evaluation of neutralizing antibodies against highly pathogenic coronaviruses: a detailed protocol for a rapid evaluation of neutralizing antibodies using vesicular stomatitis virus pseudovirus-based assay","volume":"11","author":"Almahboub","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2025.127975_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1291534","article-title":"Robust memory humoral immune response to SARS-CoV-2 in the tonsils of adults and children","volume":"14","author":"Altorki","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127975_bb0230","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02170-24","article-title":"Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals","volume":"16","author":"Aljehani","year":"2025","journal-title":"mBio"},{"issue":"45","key":"10.1016\/j.vaccine.2025.127975_bb0235","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1016\/j.vaccine.2014.08.058","article-title":"Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB\/c mice","volume":"32","author":"Kim","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127975_bb0240","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-017-0029-1","article-title":"Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model","volume":"2","author":"Munster","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127975_bb0245","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.antiviral.2017.12.007","article-title":"A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization","volume":"150","author":"Liu","year":"2018","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127975_bb0250","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1080\/22221751.2019.1620083","article-title":"Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection","volume":"8","author":"Jia","year":"2019","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127975_bb0255","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41467-023-36754-z","article-title":"Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase","volume":"14","author":"Myeni","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127975_bb0260","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00554-20","article-title":"Single-dose, intranasal immunization with recombinant parainfluenza virus 5 expressing Middle East respiratory syndrome coronavirus (MERS-CoV) spike protein protects mice from fatal MERS-CoV infection","volume":"11","author":"Li","year":"2020","journal-title":"mBio"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127975_bb0265","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","article-title":"Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus","volume":"12","author":"Agrawal","year":"2016","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25012733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25012733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:11:39Z","timestamp":1766077899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25012733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":53,"alternative-id":["S0264410X25012733"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127975","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal CD40-targeted recombinant MERS-CoV S1 protein is superior to intramuscular immunization in eliciting systemic and mucosal immune responses in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127975","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127975"}}